Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS
- 23 August 2021
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health)
- Vol. 144 (8), 655-658
- https://doi.org/10.1161/circulationaha.120.053294
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- FDA’s Benefit–Risk Framework for Human Drugs and Biologics: Role in Benefit–Risk Assessment and Analysis of Use for Drug ApprovalsTherapeutic Innovation & Regulatory Science, 2020
- Ticagrelor in Patients with Stable Coronary Disease and DiabetesThe New England Journal of Medicine, 2019
- Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task ForceValue in Health, 2016
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2009